Veronique Preat
University of Louvain, Louvain drug research Institute, Belgium
Title: Local and targeted delivery of nanomedicines for the treatment of glioblastoma
Biography
Biography: Veronique Preat
Abstract
Glioblastoma (GBM) treatment includes, when possible, surgical resection of the tumor followed by chemoradiotherapy but the survival remains low mainly due to local recurrences. The local and targeted systemic delivery of anticancer drug-loaded nanomedicines to treat GBM after surgical resection of the tumor is a promising strategy. Among the strategies that have been adopted in the last two decades to find new and efficacious therapies for the treatment of GBM, the local delivery of chemotherapeutic drugs in the tumor resection cavity emerged. We developed two formulations of anticancer nanomedicines that can be injected perisurgically in the resection cavity of orthotopic GBM. Both PEG-DMA photopolymerisable hydrogel containing paclitaxel loaded nanoparticles and lauroyl-Gemcitabine lipid nanocapsules that spontaneously form a gel significantly improved the survival of the GBM-bearing mice. Another nanomedicine-based strategy could also improve GBM outcome. Targeted nanotheranostics are promising multifunctional system characterized by nano-size, possibility of surface functionalization, diagnostic and therapeutic capabilities. Due to the loss of BBB integrity in the GBM area, we showed that active targeting or magnetic targeting of SPIO/paclitaxel loaded nanoparticles enhanced the biodistribution of the nanoparticles in the brain and enhanced the survival time of GBM bearing mice after IV administration. The potential of other nanomedicine-based treatments of GBM will be discussed.